We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Avacta
AVA6000 set to start US Phase I studies in early-2022MaxCyte
Nkarta signs SPL to accelerate its NK cell therapiesAllergy Therapeutics
Positive top line G309 results for Grass MATA MPLRedx Pharma
R&D update: RXC004 and RXC007 in the spotlightANGLE
Poised to disrupt existing tumour assay protocolsAvacta
Foundations for two healthy businesses now in placeFutura Medical
A year of delivery, with key milestones achievedAllergy Therapeutics
FY21 results show continued strong growthArecor Therapeutics
H121 results underline quality of management executionAllergy Therapeutics
VLP Peanut heading towards US Phase I studies